Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Emulation of a Comparative Effectiveness Study of Pembrolizumab and Chemotherapy vs. Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer

NCT05908799 is registered in ClinicalTrials.gov with Aetion, Inc. as lead sponsor.

NCT NCT05908799
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05908799 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Emulation of a Comparative Effectiveness Study of Pembrolizumab and Chemotherapy vs. Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer
Lead sponsor
Aetion, Inc.
Phase
Observational
Overall status
Completed
Start date
June 5, 2023
Completion date
August 31, 2023
Enrollment
1,854 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic lung cancer, non-small cell lung cancer